嘉实中证疫苗与生物技术ETF(562860)利润分配表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 收入 |
33,035,943.76 |
22,629,963.55 |
-123,376,736.18 |
-144,625,740.51 |
| 利息合计 |
10,830.39 |
5,793.32 |
177,165.32 |
168,659.20 |
| 其中:存款利息收入 |
10,830.39 |
5,793.32 |
17,958.64 |
9,452.52 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-40,062,799.92 |
-25,650,179.40 |
-59,410,482.24 |
-28,746,074.15 |
| 其中:股票投资收益 |
-42,537,477.65 |
-27,260,408.65 |
-64,013,793.26 |
-31,139,399.51 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
71,815.89 |
71,815.89 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
2,474,677.73 |
1,610,229.25 |
4,531,495.13 |
2,321,509.47 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
73,005,300.02 |
48,290,900.86 |
-64,275,919.00 |
-116,157,993.63 |
| 其他收入 |
82,613.27 |
-16,551.23 |
132,499.74 |
109,668.07 |
| 费用 |
1,720,326.19 |
878,266.91 |
2,184,708.39 |
1,209,183.37 |
| 管理人报酬 |
1,309,981.06 |
670,571.74 |
1,696,320.60 |
927,755.11 |
| 基金托管费 |
261,996.13 |
134,114.29 |
339,264.08 |
185,551.03 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
148,349.00 |
73,580.88 |
148,550.00 |
95,303.52 |
| 利润总额 |
31,315,617.57 |
21,751,696.64 |
-125,561,444.57 |
-145,834,923.88 |